Identification of endogenous surrogate ligands for human P2Y receptors through an in silico search

Journal of Pharmacological Sciences

Volumn 95, Issue 1, 2004, Pages 81-93

  Hiramoto, Takeshi ^a   Nonaka, Yosuke ^a   Inoue, Kazuko ^a   Yamamoto, Takefumi ^b   Omatsu Kanbe, Mariko ^b   Matsuura, Hiroshi ^b   Gohda, Keigo ^c   Fujita, Norihisa ^a  

^a RITSUMEIKAN UNIVERSITY   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c CAMM Kansai   (Japan)

Author keywords

5 phosphoribosyl 1 pyrophosphate; AutoDock; G protein coupled receptor; In silico screening; P2Y1 receptor

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LIGAND; PHOSPHORIBOSYL PYROPHOSPHATE; PURINE P2X2 RECEPTOR; PURINE P2Y RECEPTOR; PURINE P2Y1 RECEPTOR; PURINE P2Y12 RECEPTOR; PURINE P2Y2 RECEPTOR; PURINE P2Y6 RECEPTOR; RHODOPSIN;

ALPHA HELIX; ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CHO CELL; CONTROLLED STUDY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SCREENING; IN SILICO SCREENING; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY;

EID: 3042829023     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.95.81     Document Type: Article

References (41)

1. Muller G. Towards 3D structures of G protein-coupled receptors: multidisciplinary approach. Curr Med Chem. 2000;7:861-888.
2. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science. 2000;289:739-745.
3. Bowie JU. Helix-bundle membrane protein fold templates. Protein Sci. 1999;812:2711-2719.
4. Koshi JM, Bruno WJ. Major structural determinants of transmembrane proteins identified by principal component analysis. Proteins. 1999;3:333-340.
5. Pilpel Y, Ben-Tal N, Lancet D. kPROT: a knowledge-based scale for the propensity of residue orientation in transmembrane segments. Application to membrane protein structure prediction. J Mol Biol. 1999;4:921-935.
6. Hirokawa T, Uechi J, Sasamoto H, Suwa M, Mitaku S. A triangle lattice model that predicts transmembrane helix configuration using a polar jigsaw puzzle. Protein Eng. 2000;11:771-778.
7. Overington J, Donnelly D, Johnson MS, Sali A, Blundell TL. Environment-specific amino acid substitution tables: tertiary templates and prediction of protein folds. Protein Sci. 1992;2:216-226.
8. Donnelly D, Overington JP, Blundell TL. The prediction and orientation of α-helices from sequence alignments: the combined use of environment-dependent substitution tables, Fourier transform methods and helix capping rules. Protein Eng. 1994;5:645-653.
9. Hiramoto T, Kikuchi T, Fujita N. Prediction of 3D structure and ligand binding sites in purinoceptors. Memoirs of the Institute of Science & Engineering, Ritsumeikan University 60. 2001:47-57. (text in Japanese with English abstract)
10. 1 receptor based on Fourier transform analysis. J Protein Chem. 2002;8:537-545.
11. Goodsell DS, Olson AJ. Automated docking of substrates to proteins by simulated annealing. Proteins. 1990;3:195-202.
12. Morris GM, Goodsell DS, Huey R, Olson AJ. Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J Comput Aided Mol Des. 1996;4:293-304.
13. Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comp Chem. 1998;19:1639-1662.
14. Goodsell DS, Lauble H, Stout CD, Olson AJ. Automated docking in crystallography: analysis of the substrates of aconitase. Proteins. 1993;1:1-10.
15. Lunney EA, Hagen SE, Domagala JM, et al. A novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs. J Med Chem. 1994;17:2664-2677.
16. Gieldon A, Kazmierkiewicz R, Slusarz R, Ciarkowski J. Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors. J Comput Aided Mol Des. 2001;15:1085-1104.
17. Abbracchio MP, Burnstock G. Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacol Ther. 1994;64:445-475.
18. Burnstock G, King BF. Numbering of cloned P2 purinoceptors. Drug Dev Res. 1996;38:67-71.
19. 14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci. 2003;24:52-55.
20. Barnard EA, Simon J, Webb TE. Nucleotide receptors in the nervous system. An abundant component using diverse transduction mechanisms. Mol Neurobiol. 1997;15:103-129.
21. Hollopeter G, Jantzen HM, Vincent D. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409:202-207.
22. Seifert R, Lee TW, Lam VT, Kobilka BK. Reconstitution of β2-adrenoceptor-GTP-binding-protein interaction in Sf9 cells-high coupling efficiency in a β2-adrenoceptor-Gsα fusion protein. Eur J Biochem. 1998;255:369-382.
23. Fujita N, Yamamoto Y, Murakami T, Hiramoto T. Characterization of fusion protein between purinoceptor and Gα proteins. Pharmacologist. 2002;442;144.
24. Vohringer C, Schafer R, Reiser G. A chimeric rat brain P2Y1 receptor tagged with green-fluorescent protein: high-affinity ligand recognition of adenosine diphosphates and triphosphates and selectivity identical to that of the wild-type receptor. Biochem Pharmacol. 2000;59:791-800.
25. 1 receptor. Mol Pharmacol. 1996;50:1323-1329.
26. 1 receptor. Mol Pharmacol. 1997;52:499-507.
27. 1 receptor in surface expression and activation processes. J Biol Chem. 1999;274:14639-14647.
28. 1 receptor. Br J Pharmacol. 1997;121:338-344.
29. Freist W, Verhey JF, Stuhmer W, Gauss DH. ATP binding site of P2X channel proteins: structural similarities with class II aminoacyl-tRNA synthetases. FEBS Lett. 1998;434:61-65.
30. Hove-Jensen B. Phosphoribosylpyrophosphate (PRPP)-less mutants of Escherichia coli. Mol Microbiol. 1989;3:1487-1492.
31. Khorana HG, Fernandes JF, Kornberg A. Pyrophosphorylation of ribose 5-phosphate in the enzymatic synthesis of 5-phosphorylribose 1-pyrophosphate. J Biol Chem. 1958;230:941-948.
32. Switzer RL. Regulation and mechanism of phosphoribosylpyrophosphate synthetase. I. Purification and properties of the enzyme from Salmonella typhimurium. J Biol Chem. 1969;244:2854-2863.
33. Switzer RL, Sogin DC. Regulation and mechanism of phosphoribosylpyrophosphate synthetase. V. Inhibition by end products and regulation by adenosine diphosphate. J Biol Chem. 1973;248:1063-1073.
34. Tatibana M, Kita K, Taira M, et al. Mammalian phosphoribosylpyrophosphate synthetase. Adv Enzyme Regul. 1995;35:229-249.
35. Jenwitheesuk E, Samudrala R. Improved prediction of HIV-1 protease-inhibitor binding energies by molecular dynamics simulations. BMC Struct Biol. 2003;3:2.
36. 1 receptor. Biochemistry. 1999;38:3498-3507.
37. 1 receptor antagonists. J Med Chem. 2000;43:746-755.
38. 1 receptor ligands. J Med Chem. 2000;43:829-842.
39. 1 receptor with a high affinity radiolabeled antagonist. Mol Pharmacol. 2002;62:1249-1257.
40. 1 receptor antagonist. Br J Pharmacol. 2002;135:2004-2010.
41. 12 receptor: a novel member of the P2Y family of receptors activated by extracellular nucleotides. Mol Pharmacol. 2001;60:416-420.